Policy Watch: FDA moves toward clinical trials of the psychedelic ibogaine - Chemical & Engineering News

Boldrey, Fraser, and Gelbord Named to 2026–2027 Global Top 200 Cannabis Lawyers List - Dykema

The FDA may soon approve its first psychedelic drug. But how to regulate it? - NBC News

Scaling psychedelics comes with uncertainty ‘baked into the sauce’ - Fierce Pharma

Blinding, Ethics, and Safety Safeguards in Psychedelic Clinical Research - Psychiatric Times

Health Care Weekly: Liquidia Drug Marketing for Lung Condition Found to Violate Rival’s Patent After ‘At-Risk’ Launch; CMS Slashes Scope of GLOBE Pricing Model; FDA Seeks Input on Psychedelic Made From Tree Bark; Medline Hospital Bed Recall Tops 1 - The Capitol Forum

Rhode Island Grapples With Hemp Policy As Federal Ban On THC Products Looms - Marijuana Moment

Luminous Mind, Inc. Announces U.S. Patent for Non-Hallucinogenic Psychedelic Mushrooms - PR Newswire

US advances first government-funded trials of psychedelic drug ibogaine - KWSN

Texas can’t spend $50M for ibogaine trials. Feds may fill the gap - Perk Valley Now

Citi Surprised At QXO’s Decision To Acquire TopBuild, But Believes Deal Is Positive – How Much Upside Does It See In The Stock? - Stocktwits

GOP Congressman Says Marijuana Rescheduling Should Expand To 'Across-The-Board' Review Of Psychedelics And Other Drugs - Marijuana Moment

Trump Complains That Democratic-Run Cities Smell Like Marijuana - Marijuana Moment

Medical Marijuana Improves Cancer-Related Symptoms And Helps Reduce Use Of Opioids, Federally Funded Study Shows - Marijuana Moment

Emyria Taps Former U.S. VA Secretary Shulkin to Bolster U.S. Psychedelic Strategy - TipRanks

PEAKING: PSYCHEDELICS AND THE PURSUIT OF HAPPINESS takes viewers inside dosing rooms to watch psychedelic healing as it happens - PR Newswire